Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE versus TESULOID.
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category D/X
Category C
Androgen
Androgen